EXCHANGE OF SCIENTIFIC MATERIALS AND DATA AGREEMENT (Materials Are Not for Use in Human Subjects)Exchange of Scientific Materials and Data Agreement • December 16th, 2010 • Medgenics, Inc. • Biological products, (no disgnostic substances)
The Parties shall exercise reasonable efforts to carry out the activities described in the work scope provided for in Exhibit 1, which is hereby incorporated into this Agreement by reference. The Principal Investigator for BCM shall be Philip Ng, PhD (“BCM Principal Investigator”). The Principal Investigator for Medgenics shall be Baruch Stern, PhD (“Medgenics Principal Investigator”).
FIRST AMENDMENT TO STANDSTILL AND OPTION AGREEMENTStandstill and Option Agreement • December 16th, 2010 • Medgenics, Inc. • Biological products, (no disgnostic substances)
This FIRST AMENDMENT TO STANDSTILL AND OPTION AGREEMENT (this “Amendment”) effective 22nd day of October, 2009 (the “Effective Date”), is made and entered into by and among Baxter Healthcare Corporation, a Delaware Corporation with a place of business at One Baxter Parkway, Deerficld, IL 60015 (“BHC”), Baxter Healthcare S.A., a corporation organized under the laws of Switzerland with a place of business at Thurgauerstrasse 130, 8152 Glattpark (Opfikon) Switzerland (“BHSA”), Baxter Innovations GmbH, a corporation organized under the laws of Austria with a place of business at Industriestrasse 67, 1221 Vienna, Austria (“Innovations” and, together with BHC and BHSA, “Baxter”) and Medgenics, Inc., a Delaware corporation with a place of business at Teradion Business Park, P.O. Box 14, Misgav 20179 Israel (“Medgenics”). Baxter and Medgenics are each sometimes referred to herein as a “Party” and, collectively, as the “Parties”.
THIRD AMENDMENT TO STANDSTILL AND OPTION AGREEMENTStandstill and Option Agreement • December 16th, 2010 • Medgenics, Inc. • Biological products, (no disgnostic substances)
This THIRD AMENDMENT TO STANDSTILL AND OPTION AGREEMENT (this “Third Amendment”) effective this 20th day of October, 2010 (the “Effective Date”), is made and entered into by and among Baxter Healthcare Corporation, a Delaware Corporation with a place of business at One Baxter Parkway, Deerfield, IL 60015 (“BHC”), Baxter Healthcare S.A., a corporation organized under the laws of Switzerland with a place of business at Thurgauerstrasse 130, 8152 Glattpark (Opfikon) Switzerland (“BHSA”), Baxter Innovations GmbH, a corporation organized under the laws of Austria with a place of business at Industriestrasse 67, 1221 Vienna, Austria (“Innovations” and, together with BHC and BHSA, “Baxter”) and Medgenics, Inc., a Delaware corporation with a place of business at Teradion Business Park, P.O. Box 14, Misgav 20179 Israel (“Medgenics”). Baxter and Medgenics are each sometimes referred to herein as a “Party” and, collectively, as the “Parties”.
STANDSTILL AND OPTION AGREEMENTStandstill and Option Agreement • December 16th, 2010 • Medgenics, Inc. • Biological products, (no disgnostic substances) • Illinois
THIS STANDSTILL AND OPTION AGREEMENT (this “Agreement”) is made and entered into this 22nd day of October, 2009 (the “Effective Date”), by and between Baxter Healthcare Corporation, a Delaware Corporation with a place of business at One Baxter Parkway, Deerfield, IL 60015 (“Baxter”) and Medgenics, Inc., a Delaware, corporation with a place of business at Teradion Business Park, P.O. Box 14, Misgav 20179 Israel (“Medgenics”). Baxter and Medgenics are each sometimes referred to herein as a “Party” and, collectively, as the “Parties”.
SECOND AMENDMENT TO STANDSTILL AND OPTION AGREEMENTStandstill and Option Agreement • December 16th, 2010 • Medgenics, Inc. • Biological products, (no disgnostic substances)
This SECOND AMENDMENT TO STANDSTILL AND OPTION AGREEMENT (this “Second Amendment”) effective this 29th day of December, 2009 (the “Effective Date”), is made and entered into by and among Baxter Healthcare Corporation, a Delaware Corporation with a place of business at One Baxter Parkway, Deerfield, IL 60015 (“BHC”), Baxter Healthcare S.A., a corporation organized under the laws of Switzerland with a place of business at Thurgauerstrasse 130, 8152 Glattpark (Opfikon) Switzerland (“BHSA”), Baxter Innovations GmbH, a corporation organized under the laws of Austria with a place of business at Industriestrasse 67, 1221 Vienna, Austria (“Innovations” and, together with BHC and BHSA, “Baxter”) and Medgenics, Inc., a Delaware corporation with a place of business at Tcradion Business Park, P.O. Box 14, Misgav 20179 Israel (“Medgenics”). Baxter and Medgenics are each sometimes referred to herein as a “Party” and, collectively, as the “Parties”.
